Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Roberts Glore & Co. Inc. IL

Roberts Glore & Co. Inc. IL raised its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,161 shares of the company’s stock after purchasing an additional 80 shares during the quarter. Roberts Glore & Co. Inc. IL’s holdings in Medpace were worth $1,383,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of MEDP. R Squared Ltd acquired a new position in Medpace during the 4th quarter valued at approximately $30,000. SBI Securities Co. Ltd. acquired a new position in Medpace during the 4th quarter valued at approximately $31,000. Stone House Investment Management LLC acquired a new position in Medpace during the 3rd quarter valued at approximately $33,000. Ashton Thomas Securities LLC acquired a new position in Medpace during the 3rd quarter valued at approximately $37,000. Finally, Jones Financial Companies Lllp increased its stake in Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock valued at $38,000 after purchasing an additional 110 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird upped their price target on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Medpace currently has an average rating of “Hold” and a consensus target price of $381.44.

Medpace Price Performance

MEDP stock opened at $332.81 on Friday. The firm’s fifty day simple moving average is $341.10 and its 200-day simple moving average is $343.29. Medpace Holdings, Inc. has a 12 month low of $302.01 and a 12 month high of $459.77. The company has a market capitalization of $10.14 billion, a P/E ratio of 26.35, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.